Dr. Zoubeidi led an international team that has published their discovery providing mechanistic insights into prostate cancer resistant to powerful hormone therapy, and proposes a potential treatment regime for reversing currently treatment-resistant phenotypes. This work was published online on September 6, 2021 in the high-impact journal Nature Cell Biology , along with a News and Views article focusing on this publication. The team investigated a…
Read More
Eyam Vaccine and Immunotherapeutics (EYAM), a next-generation vaccine biotechnology company, announced today an agreement with Veristat, a scientific-minded, global clinical research organization (CRO), to plan and coordinate clinical trials of their vaccine program against SARS-CoV-2. “This agreement builds a partnership with a global clinical research organization that has conducted COVID-19 trials around the world. Working with Veristat to plan and implement our clinical…
Read More

A Canadian First in CAR-T Cell Treatment for Adult Leukemia and Lymphoma

A study co-led by Dr. Kevin Hay from Vancouver Coastal Health Research Institute (VCHRI) and Dr. Natasha Kekre at The Ottawa Hospital is investigating the use of specialized chimeric antigen receptor T (CAR-T) cells to treat CD19 positive (CD19+) acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). This first-of-its-kind clinical trial in Canada involves manufacturing and administering a CLIC-1901 cell therapy, which…
Read More
STEMCELL Technologies announces the launch of human pluripotent stem cell (hPSC) characterization and banking services in partnership with WiCell®. These services, offered through STEMCELL’s Contract Assay Services division, will provide researchers with comprehensive cell quality assessments and enable them to generate cell banks using standardized practices. Ultimately, this will reduce variability and improve reproducibility for various downstream applications, including disease modeling, drug discovery, toxicology…
Read More
Ever wondered how you can make artwork with biological reagents found in the lab? How about exploring the latest bleeding-edge research in science and medicine? If these topics interest you, then you won’t want to miss out on this event recap of CBR-SBME Research Day 2021! The Centre for Blood Research (CBR) and School of Biomedical Engineering (SBME) communities gathered online for CBR-SBME Research Day on…
Read More

TFRI launches 2021 Terry Fox Run Challenge

he Terry Fox Research Institute (TFRI) is happy to launch its 2021 Terry Fox Run Challenge, an annual event in which our research teams look to claim top honours by raising the most funds for cancer research. Last year, 28 teams participated in the challenge, raising over $98,000 for cancer research. For the third year in a row, the Vancouver Prostate…
Read More
Assistant Professor Dr. Carolina Tropini (Department of Microbiology and Immunology, School of Biomedical Engineering) is excited to share the Tropini lab’s vision for the future of microbiome research. In the recent manuscript for mSystems – “How the physical environment shapes the microbiota” – the Tropini lab’s research highlights the importance of measuring physical parameters for the prediction of microbial dynamics…
Read More
Researchers at UBC’s faculty of medicine and BC Cancer Research Institute have uncovered a weakness in a key enzyme that solid tumour cancer cells rely on to adapt and survive when oxygen levels are low. The findings, published today in Science Advances, will help researchers develop new treatment strategies to limit the progression of solid cancer tumours, which represent the…
Read More
The short answer: It really depends on what we define as aging. Professor Fabio Rossi, University of British Columbia, is Director, Research in the School of Biomedical Engineering and Canada Research Chair in Regenerative Medicine. He obtained his MD from his hometown university in Genoa, Italy. During undergraduate studies, he investigated the mechanisms underlying chondrocyte differentiation in the laboratory of Ranieri Cancedda. Next,…
Read More